Loading...
IVI-NSCLC Value Model2018-08-23T18:43:16+00:00

Value Assessment Platforms for Oncology

Oncology is an area of immense clinical need and a primary driver of healthcare spending, making it a prime target for assessment of the value of available medical interventions. IVI’s next Open-Source Value Project (OSVP) model will focus on non-small cell lung cancer (NSCLC). Specifically, the IVI-NSCLC model will focus on sequential treatment strategies for patients with epidermal growth factor receptor positive (EGFR+) NSCLC.

IVI’s open-source value model for EGFR+ NSCLC treatments will facilitate patient-centered, robust, and relevant evaluation of the value of care for an often devastating disease. Development of this model reflects IVI’s vision of a transparent process for understanding value in the local setting, especially from the patient perspective.

Learn More about the IVI-NSCLC Value Tool

IVI is developing a new value tool that is designed to estimate the health outcomes, risks, and costs associated with alternative treatment strategies among patients with EGFR+ non-small cell lung cancer. Details on the study can be found in the study protocol.

READ  STUDY PROTOCOL

Information of the schedule of release for the tool can be found in the project timeline.

View Project Timeline

Why Non-Small Cell Lung Cancer?

Lung cancer is the leading cause of cancer-related deaths worldwide.(1) The American Cancer Society estimates that of the 1,735,000 new cancer cases in the U.S. in 2018, 13.5% will be lung cancer. NSCLC accounts for an estimated 85% of lung cancer cases and comprises adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.(2)

Given the rapid pace of development in lung cancer treatment, the scope of the initial IVI-NSCLC model needed to be limited to a specific sub-population. Our focus on EGFR+ NSCLC provides a strong opportunity to demonstrate the typical areas of uncertainty in value assessment in oncology and the need for customized analyses to inform local decision-making. In the future, IVI may expand the model to other NSCLC subpopulations of interest.

What Will IVI Achieve?

IVI is developing a flexible model to measure the benefits, risks and costs, for a range of treatment sequences across successive lines of therapy for EGFR+ NSCLC. Centered on the patient perspective, these models will support value assessment using cost-effectiveness analysis (CEA) and multi-criteria decision-analysis (MCDA) frameworks. The model is accessible to both technical and non-technical end-users and allows evaluating the impact of scientific uncertainty, novel concepts of value, and different decision-maker perspectives on the estimates of value. The model will accommodate new clinical evidence as it emerges and allow user-driven customization to yield timely and user-relevant value assessment results.

IVI will deliver the following:

IVI will deliver a flexible open-source decision model along with technical model documentation.
IVI will deliver a publicly-released report quantifying NSCLC patient perspectives on value, based on qualitative research with patients.
IVI will deliver a publicly available web-based user interface designed to allow users with varying levels of expertise to interact with the NSCLC value model, explore questions of interest, and generate results tailored to their local setting.
IVI will provide illustrative examples of analysis to demonstrate and educate key marketplace stakeholders about the challenges of value assessment in oncology, due to patient heterogeneity, gaps in scientific evidence, uncertainty about model structure, and other sources of scientific uncertainty.

Patient Perspective at the Heart of Model Development

Patients are an indispensable voice in developing any platform or model that may affect healthcare decision-making. IVI actively seeks patients and patient organizations as partners to collaborate to develop research that seeks to understand their drivers of value. Many opportunities exist for interested patient partners to contribute to the OSVP effort, and we encourage any interested patients or patient organizations to contact us to learn about joining our existing partners.

IVI is conducting qualitative research with NSCLC patients to better understand their perspectives on value, what they consider and worry about when making treatment decisions, and how they prioritize one aspect versus another. The findings from this research will directly inform the development of the IVI-NSCLC model, particularly the content and structure of the multi-criteria decision analysis portion that allows for customized decision analysis. Findings from the qualitative research will also feed directly into a related “Quantifying the Patient Experience” study in which IVI is developing NSCLC-specific measures of quality of life incorporating different treatment modalities. The results of this latter study will be incorporated into Version 2 of the OSVP model.

Enlarge Image